Short-Acting Insulin Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Short-Acting Insulin Market Growth Analysis: How Will Revenue Expand During The Forecast Period?
The short-acting insulin market has experienced robust expansion over the last few years, advancing from $11.54 billion in 2025 to a projected $12.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. This upward trajectory during the historical period was driven by a high prevalence of diabetes, the widespread adoption of insulin therapy, hospital-centered diabetes management, the expansion of insulin access initiatives, and enhanced rates of diabetes diagnosis.
The market for short-acting insulin is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $14.87 billion, driven by a compound annual growth rate (CAGR) of 5.2%. This forecasted growth is largely fueled by a higher prevalence of type 2 diabetes, growing reliance on insulin, an uptick in home-based diabetes management, advances in insulin delivery systems, and a stronger preference for fast-acting insulin options. Among the key developments shaping this period are an escalating need for controlling blood sugar after meals, broader use of rapid-acting insulin analogues, wider uptake of pre-filled insulin pens, more frequent adoption of intensive insulin therapy protocols, and a heightened emphasis on achieving strict glycemic targets.
Download A Free Sample Report For Comprehensive Market Insights:
Short-Acting Insulin Market Expansion Drivers: What Is Shaping Future Growth?
The upward trend in type 1 diabetes cases is anticipated to propel the expansion of the short-acting insulin market in the coming years. Type 1 diabetes is an autoimmune disorder in which the body attacks its own insulin-producing cells, making lifelong insulin treatment essential. This condition is becoming more common due to genetic predispositions, environmental factors, and a rise in autoimmune diseases. Short-acting insulin addresses the needs of type 1 diabetes by offering swift blood glucose regulation and simulating the body’s natural insulin secretion. As an illustration, Diabetes Australia, an Australian organization dedicated to diabetes awareness, reported that in December 2023, around 134,000 Australians had type 1 diabetes in 2022, a number that climbed to 135,423 by 2023. Consequently, the growing incidence of type 1 diabetes is fueling the short-acting insulin market’s growth.
Short-Acting Insulin Market Segment Analysis And Revenue Opportunities
The short-acting insulin market covered in this report is segmented –
1) By Formulation: Regular Insulin, Rapid-Acting Insulin
2) By Dosage Form: Vials, Pre-filled Pens, Cartridges
3) By Route Of Administration: Subcutaneous, Intravenous
4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes
5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies
Subsegments:
1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin
2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine
Short-Acting Insulin Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Major players in the short-acting insulin market are placing increased emphasis on the development of cutting-edge products, specifically interchangeable rapid-acting insulin biologics, which are designed to improve glycemic control and give diabetic patients greater flexibility in treatment substitution. An interchangeable rapid-acting insulin biologic is a biologically-based insulin formulation that rapidly reduces blood glucose levels after meals, having received regulatory approval to be swapped for a comparable insulin product without the need for a fresh prescription, thereby offering adaptable diabetes care and ensuring steady glycemic management. A notable example occurred in July 2025, when Biocon Biologics—a biosimilars company based in the United States but headquartered in India and the U.S.—obtained FDA approval for Kirsty (insulin aspart xjhz), which stands as the first and only interchangeable rapid-acting insulin aspart available in the United States. Kirsty functions as a biosimilar to NovoLog (insulin aspart), with clinical and analytical evidence showing no meaningful differences in safety, efficacy, purity, or potency. This product comes in a 100 units/mL formulation, provided as a single-patient-use prefilled pen for subcutaneous injection and as a multi-dose vial suitable for both subcutaneous and intravenous administration, with the goal of enhancing glycemic control in both adults and children suffering from diabetes mellitus.
Short-Acting Insulin Market Leading Players Shaping Industry Direction
Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited
Access The Complete Short-Acting Insulin Market Report:
Short-Acting Insulin Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
